• PKM2 inhibitor (compound 3k) Workflow Guide

  2026-09-21

  Build cancer-metabolism and immunometabolism assays around a selective pyruvate kinase M2 inhibitor with defined potency, cell-line response, and xenograft precedent. This guide connects aerobic glycolysis disruption in tumor cells with the USP7–PKM2 macrophage pathway while separating established findings from practical optimization recommendations.

• Phosbind Acrylamide for Wheat Kinase Assays

  2026-09-21

  Phosbind Acrylamide provides an antibody-independent route to protein phosphorylation analysis in wheat signaling research. This article translates the TaCKX11-D–TaMPK3/6 findings into a practical SDS-PAGE phosphorylation detection strategy, including controls, interpretation limits, and assay design decisions.

• Vardenafil HCl Trihydrate: PDE5 Assay Guide

  2026-09-20

  Build a connected workflow from biochemical PDE5 inhibition to cGMP signaling, smooth muscle relaxation, and native-membrane proteoform analysis. Vardenafil HCl Trihydrate combines strong enzymatic potency with a practical solubility profile, while careful PDE6 counter-screening helps distinguish target activity from membrane-context effects.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-09-19

  A 2024 ACS Applied Materials & Interfaces study shows that lithium enhances BMSC osteogenesis by increasing exosomal Wnt10a secretion through MARK2-dependent Rab11a/Rab11FIP1 trafficking and subsequent Wnt/β-catenin activation. Lithium-conditioned exosomes and GelMA hydrogels containing these vesicles improved osteogenic responses and bone repair, providing a mechanistic framework for engineering cell-derived therapies.

• Heparin Sodium as a Control in Nanovesicle Assays

  2026-09-18

  Heparin sodium is more than a standard anticoagulant for thrombosis research: it can help investigators interrogate heparan sulfate-dependent nanovesicle uptake while preserving rigorous coagulation controls. This article connects the A5066 reagent to emerging Sertoli-cell nanovesicle research and practical assay design.

• Rosiglitazone: From PPARγ Biology to Translation

  2026-09-18

  Rosiglitazone, also known as Brl-49653, offers a defined way to interrogate PPARγ biology across adipogenesis, insulin sensitivity, and rare lipodystrophy models. This thought-leadership guide connects receptor mechanism with the 2026 characterization of the PPARG R212W variant and provides practical strategies for using Rosiglitazone to distinguish impaired receptor abundance, transcriptional output, mitochondrial dysfunction, and metabolic rescue.

• Stat3 Mediates Fyn-Driven Dopaminergic Neurodegeneration

  2026-09-17

  This zebrafish study identifies Stat3 as a downstream effector linking constitutively active Fyn kinase to dopaminergic neuron loss, mitochondrial abnormalities, and microglial inflammation. Its combination of cell-type-specific genetics, live imaging, transcriptomics, and pathway inhibition provides a useful mechanistic framework for Parkinson’s disease research while highlighting important limits in translating larval zebrafish findings to mammalian disease.

• E-64d as a Probe of Lysosomal Protease Death

  2026-09-17

  E-64d is a membrane-permeable cysteine protease inhibitor that can dissect calpain and cathepsin contributions to intracellular cell death. This article connects E-64d assay design with the lysoptosis framework, emphasizing how to distinguish protease dependence from lysosomal membrane damage.

• Fucoidan, the Gut–Liver Axis, and Chemotherapy Injury

  2026-09-16

  A 2026 International Immunopharmacology study identifies intestinal barrier failure and neutrophil extracellular trap accumulation as linked drivers of irinotecan-induced steatohepatitis. The work shows that Fucoidan can reduce this gut–liver inflammatory sequence by preserving tight junction integrity, limiting lipopolysaccharide translocation, partially reshaping gut microbiota, and suppressing hepatic NETs.

• Thioredoxin 1 and Late-Stage Lens Iron Recovery

  2026-09-16

  This preprint identifies thioredoxin 1 (Trx1) as a potential regulator of late-stage recovery from oxidative damage and iron imbalance in the lens, with ferritin heavy chain (FTH1) implicated as a downstream mediator. Its staged in vivo and in vitro design suggests that age-related cataract biology is temporally dynamic, although the proposed Trx1–FTH1 pathway requires validation in peer-reviewed and clinically relevant models.

• EZ Cap™ Mouse CD252(OX40L) mRNA: Assay Strategy

  2026-09-15

  Explore how EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) can support mechanistic immune co-stimulation studies. This guide distinguishes OX40L-specific assay design from related mRNA vaccine evidence and translates the literature into practical controls and readouts.

• EGTA and Calcium Flux: From Channel Biology to Translation

  2026-09-15

  EGTA, or egtazic acid, offers translational researchers a practical way to interrogate calcium-dependent injury without confusing calcium availability with channel subtype activity. This article connects calcium chelation to neuroprotection, cardiac vagal physiology, assay design, and more disciplined model selection.

• Fucoidan Workflows for Breast Cancer Research

  2026-09-14

  Build reproducible Fucoidan assays around MCF-7 cytotoxicity, migration, colony formation, and caveolin-1 analysis. This workflow also shows how to connect breast cancer findings with apoptosis, angiogenesis, and immune-modulation studies without overextending the evidence.

• 17-AAG (Tanespimycin): Reliable Cell Assays

  2026-09-14

  A scenario-based guide to improving viability, proliferation, and cytotoxicity experiments with 17-AAG (Tanespimycin), SKU A4054. It connects HSP90 biology with formulation control, dose-response design, endpoint interpretation, and practical product selection for reproducible cancer research.

• GW 4869: Exosome Workflow for Lupus Nephritis

  2026-09-13

  GW 4869 hydrochloride hydrate provides a practical pharmacologic gate for testing whether neutral sphingomyelinase-dependent vesicle release drives endothelial injury. This workflow combines donor-cell perturbation, extracellular vesicle normalization, HMGB1/TRIM27 pathway testing, and controls that distinguish exosome effects from broader sphingolipid signaling.

7951 records 1/531 page Next 12345 下5页 Last page